Podcasts

Episode 42 | NTRK 1, 2, 3 and Other Rare Mutations in NSCLC

This episode is hosted by: A/Prof Steven Kao, Prof Wendy Cooper, and Prof Ben Solomon

NTRK 1, 2, 3 and Other Rare Mutations in NSCLC

Episode Summary

This episode provides an overview of the treatment options for rare subtypes of oncogene-driven NSCLC that are now readily identified in the MBS-reimbursed small gene panel including NTRK1, 2, 3, and other rare mutations in NSCLC.

Show Hosts

This episode’s host are:

  • A/Prof Steven Kao, Medical Oncologist from Chris O’Brien Lifehouse and Clinical Associate Professor Sydney Medical School, Faculty of Medicine and Health
  • Prof Wendy Cooper, senior staff specialist in Tissue Pathology and Diagnostic Oncology at Royal Prince Alfred Hospital in Sydney, Anatomical Clinical Stream Lead for NSW Health Pathology, a Clinical Professor at the University of Sydney and a Conjoint Professor at the University of Western Sydney
  • Prof Ben Solomon, head of the lung Medical Oncology Service and a Group Leader of the Molecular Therapeutics and Biomarkers Laboratory in the Research Division at Peter MacCallum Cancer Centre as well as a Founding Board member of TOGA.

Sponsor

This episode is proudly sponsored by Bayer. 

 

Play Episode 42 | NTRK 1, 2, 3 and Other Rare Mutations in NSCLC

More Podcasts

Dr Rebecca Tay is joined by Professor Ben Solomon and A/Prof Michael Ng to discuss clinical and genetic factors affecting treatment choice for ALK-Positive NSCLC
Dr Deme Karikios is joined by Dr Lauren Brown and Dr Stephen Barnett to discuss IO in early-stage NSCLC in the Australian context.
A/Prof Rachel Wong is joined by Dr Patrick Hosking, Dr Mal Itchins, and Dr Sagun Parakh discuss the diagnostic markers when identifying LC-NEC.
We dive into the latest survival data from the ADRIATIC trial, as presented at ASCO 2024, which could change the treatment landscape for LS-SCLC. Joining
This episode is hosted by: Dr Pei Ni Ding, Dr Samantha Bowyer, and Mr Naveed Alam.
This episode is hosted by: Dr Rebecca Tay, Professor Nick Pavlakis, and Dr Deme Karikios.